Zobrazeno 1 - 10
of 1 398
pro vyhledávání: '"McGuirk JP"'
Autor:
Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Wesson W; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Lutfi F; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Porter DL; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Bachanova V; Division of Hematology, Oncology, and Transplantation, Department of Medicine, University of Minnesota, Minneapolis, MN., Nastoupil LJ; The University of Texas MD Anderson Cancer Center, Houston, TX., Perales MA; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY., Maziarz RT; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Brower J; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Shah GL; Department of Medicine, Adult Bone Marrow Transplantation Service, Memorial Sloan Kettering Cancer Center, New York, NY., Chen AI; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Oluwole OO; Division of Hematology/Oncology, Vanderbilt University Medical Center, Nashville, TN., Schuster SJ; Abramson Cancer Center and Center for Cell Therapy and Transplant, University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA., Bishop MR; David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, The University of Kansas Cancer Center, Westwood, KS., Riedell PA; David and Etta Jonas Center for Cellular Therapy, The University of Chicago, Chicago, IL.
Publikováno v:
Blood advances [Blood Adv] 2024 Oct 22; Vol. 8 (20), pp. 5346-5354.
Autor:
Zulfiqar F; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Shahzad M; Division of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Florida, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Amin MK; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Vyas A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Sarfraz Z; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Zainab A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Qasim H; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Kaur D; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Khavandgar N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Lutfi F; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Hematti P; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, Florida, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, United States; Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, United States. Electronic address: mmushtaq@kumc.edu.
Publikováno v:
Transplant immunology [Transpl Immunol] 2024 Oct 21; Vol. 87, pp. 102137. Date of Electronic Publication: 2024 Oct 21.
Autor:
Rashid A; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Wesson W; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Abdallah AO; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Snyder J; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Venkatesh P; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS., Mushtaq MU; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Shune L; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Witek MA; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS., McGuirk JP; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS., Soper SA; Kansas Institute for Precision Medicine, University of Kansas Medical Center, Kansas City, KS., Cui W; Department of Pathology & Laboratory Medicine, University of Kansas Medical Center, Kansas City, KS., Ahmed N; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Cancer Center, Westwood, KS; United States Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS. Electronic address: nahmed5@kumc.edu.
Publikováno v:
Clinical lymphoma, myeloma & leukemia [Clin Lymphoma Myeloma Leuk] 2024 Oct 11. Date of Electronic Publication: 2024 Oct 11.
Autor:
Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; Division of Hematology and Oncology, Moffitt Cancer Center, University of South Florida, Tampa, Florida, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Khan MA; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Sarfraz Z; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Zulfiqar F; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Qasim H; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Bansal R; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Brownback K; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Abhyankar SH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA., Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA; The Mikael Rayaan Foundation Global Transplantation and Cellular Therapy Consortium, Kansas City, Kansas, USA. Electronic address: mmushtaq@kumc.edu.
Publikováno v:
Transplant immunology [Transpl Immunol] 2024 Oct 04; Vol. 87, pp. 102135. Date of Electronic Publication: 2024 Oct 04.
Autor:
Sidana S; Stanford University, Palo Alto, California, United States., Patel KK; The University of Texas, MD Anderson Cancer Center, Houston, Texas, United States., Peres LC; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States., Bansal R; Mayo Clinic Hospital, New York, New York, United States., Kocoglu MH; University of Maryland, Baltimore, Maryland, United States., Shune L; University of Kansas, Westwood, Kansas, United States., Atrash S; Atrium Health, Charlotte, North Carolina, United States., Smith K; Medical College of Wisconsin, Milwaukee, Wisconsin, United States., Midha S; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Ferreri CJ; Atrium Health Wake Forest Baptist Levine Cancer Institute, Charlotte, North Carolina, United States., Dhakal B; Medical College of Wisconsin, Wauwatosa, Wisconsin, United States., Dima D; Cleveland Clinic Taussig Cancer Institute, Cleveland, Ohio, United States., Costello P; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Wagner C; Huntsman Cancer Institute, Salt Lake City, Utah, United States., Reshef R; Columbia University Medical Center, New York, New York, United States., Hosoya H; Stanford University, Palo Alto, California, United States., Mikkilineni L; Stanford University School of Medicine, Palo Alto, California, United States., Atanackovic D; University of Maryland Greenebaum Comprehensive Cancer Center, Baltimore, Maryland, United States., Chhabra S; Mayo Clinic Arizona, Phoenix, Arizona, United States., Parrondo RD; Mayo Clinic Florida, Jacksonville, Florida, United States., Nadeem O; Dana-Farber Cancer Institute, Boston, Massachusetts, United States., Mann H; Virginia Commonwealth University, Richmond, Virginia, United States., Kalariya N; UT MD Anderson Cancer Center, Houston, Texas, United States., Hovanky V; Stanford University School of Medicine, Stanford, California, United States., DeAvila G; H. Lee Moffitt Cancer Center, Tampa, Florida, United States., Freeman CL; H. Lee Moffitt Cancer Center, Tampa, Florida, United States., Locke FL; Moffitt Cancer Center, Tampa, Florida, United States., Alsina M; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States., Wong S; University of California San Francisco, San Francisco, California, United States., Herr MM; Roswell Park Comprehensive Cancer Center, Buffalo, New York, United States., Htut M; City of Hope, Duarte, California, United States., McGuirk JP; University of Kansas Cancer Center, Westwood, Kansas, United States., Sborov DW; Huntsman Cancer Institute / University of Utah, Salt Lake City, Utah, United States., Khouri J; Cleveland Clinic, Cleveland, Ohio, United States., Martin T; UCSF, San Francisco, California, United States., Janakiram M; City Of Hope National Medical Center, DUARTE, California, United States., Lin Y; Mayo Clinic, Rochester, Minnesota, United States., Hansen DK; H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida, United States.
Publikováno v:
Blood [Blood] 2024 Oct 04. Date of Electronic Publication: 2024 Oct 04.
Autor:
Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; H. Lee Moffitt Cancer Center, Tampa, Florida, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Bellman P; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Al-Ramahi J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Noor J; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Vyas A; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., Mahmoudjafari Z; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., McGuirk M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA., DeJarnette S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Abhyankar S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA., Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, Kansas, USA.; Mikael Rayaan Foundation Global Health Consortium, Kansas City, USA.
Publikováno v:
Transfusion [Transfusion] 2024 Aug; Vol. 64 (8), pp. 1402-1406. Date of Electronic Publication: 2024 Jun 07.
Autor:
Zanwar S; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Sidana S; Stanford University School of Medicine, Stanford, CA, USA., Shune L; The University of Kansas Medical Center, Kansas City, KS, USA., Puglianini OC; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Pasvolsky O; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA., Gonzalez R; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Dima D; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Afrough A; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Kaur G; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., Davis JA; Medical University of South Carolina, Charleston, SC, USA., Herr M; Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA., Hashmi H; Medical University of South Carolina, Charleston, SC, USA.; Memorial Sloan Kettering Cancer Center, New York, NY, USA., Forsberg P; University of Colorado Anschutz Medical Campus, Aurora, CO, USA., Sborov D; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Anderson LD Jr; UT Southwestern Harold C. Simmons Comprehensive Cancer Center, Dallas, TX, USA., McGuirk JP; The University of Kansas Medical Center, Kansas City, KS, USA., Wagner C; The University of Utah Huntsman Cancer Institute, Salt Lake City, UT, USA., Lieberman-Cribbin A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Rossi A; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Freeman CL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Locke FL; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA., Richard S; Department of Medicine, Hematology and Medical Oncology, Icahn School of Medicine at Mount Sinai, New York, NY, USA., Khouri J; Cleveland Clinic Taussig Cancer Center, Cleveland, OH, USA., Lin Y; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA., Patel KK; Department of Lymphoma/Myeloma, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA. KPatel1@mdanderson.org., Kumar SK; Division of Hematology, Department of Medicine, Mayo Clinic, 200 1st St SW, Rochester, MN, 55905, USA. Kumar.Shaji@mayo.edu., Hansen DK; Blood and Marrow Transplant and Cellular Immunotherapy, H. Lee Moffitt Cancer Center, Tampa, FL, USA. Doris.Hansen@moffitt.org.
Publikováno v:
Journal of hematology & oncology [J Hematol Oncol] 2024 Jun 06; Vol. 17 (1), pp. 42. Date of Electronic Publication: 2024 Jun 06.
Autor:
McGuirk M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Shahzad M; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Amin MK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Khan MA; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Bellman P; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Mudaranthakam DP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., DeJarnette S; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Lutfi F; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Ahmed N; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Bansal R; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Abdelhakim H; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Gorsline C; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Shoemaker DM; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Abdallah AO; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Shune L; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Abhyankar SH; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Singh AK; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., McGuirk JP; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America., Mushtaq MU; Division of Hematologic Malignancies and Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States of America. Electronic address: mmushtaq@kumc.edu.
Publikováno v:
Transplant immunology [Transpl Immunol] 2024 Jun; Vol. 84, pp. 102039. Date of Electronic Publication: 2024 Mar 19.
Autor:
Dima D; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA. dimad@ccf.org.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA. dimad@ccf.org., Abdallah AO; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Davis JA; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA., Awada H; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Goel U; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Rashid A; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., DeJarnette S; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Anwer F; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA., Shune L; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Raza S; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA., Mahmoudjafari Z; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Williams L; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Faiman B; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., McGuirk JP; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Sauter CS; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Ahmed N; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA.; Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Westwood, KS, USA., Khouri J; Department of Hematology/Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA., Hashmi H; US Myeloma Innovations Research Collaborative (USMIRC), Westwood, KS, USA. hamzahashmi87@hotmail.com.; Division of Hematology/Oncology, Medical University of South Carolina, Charleston, SC, USA. hamzahashmi87@hotmail.com.; Memorial Sloan Kettering Cancer Center, New York, NY, USA. hamzahashmi87@hotmail.com.
Publikováno v:
Blood cancer journal [Blood Cancer J] 2024 May 31; Vol. 14 (1), pp. 90. Date of Electronic Publication: 2024 May 31.
Managing Infection Complications in the Setting of Chimeric Antigen Receptor T cell (CAR-T) Therapy.
Autor:
Ahmed N; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center., Oluwole O; Medicine, Hematology and Oncology Vanderbilt University Medical Center., Mahmoudjafari Z; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center., Suleman N; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center., McGuirk JP; Hematologic Malignancies and Cellular Therapeutics University of Kansas Cancer Center.
Publikováno v:
Clinical hematology international [Clin Hematol Int] 2024 Apr 29; Vol. 6 (2), pp. 31-45. Date of Electronic Publication: 2024 Apr 29 (Print Publication: 2024).